OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Russell Lebovitz

3 Projects | 1 Researchers | $1,834,003 Invested

2023

Amprion Inc

Russell Lebovitz, MD PhD

Evaluation of the Clinical Utility of α-Synuclein Seed Amplification Assay as an Aid in the Diagnosis of Dementia and Differentiation of Dementia Subtypes

  • Funding Amount: $570,750
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Proteostasis
  • Status: Closed

2021

Amprion Inc

Russell Lebovitz, MD PhD

Misfolded Alpha-Synuclein Aggregates in CSF as Diagnostic & Prognostic Markers for Dementia

  • Funding Amount: $631,600
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Synuclein
  • Status: Closed

2020

Amprion Inc

Russell Lebovitz, MD PhD

Development and Commercialization of a Protein Misfolding Cyclic Amplification (PMCA) Clinical Test for Detection of Aggregates of Misfolded α-Synuclein in Plasma and Plasma Exosomes

  • Funding Amount: $631,653
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: Synuclein
  • Status: Closed